Physician profile
Erin E Fleener
NPI 1295775005
$12,771.16
in general payments reported to CMS, 2019-2025
84 companies · $3,143 in 2025
The $3,143 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,567 · 2020: $570 · 2021: $1,642 · 2022: $1,406 · 2023: $1,879 · 2024: $2,565 · 2025: $3,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,945 · Long Term Medical Supply Or Device Loan: $1,363 · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,944.74 |
| Long Term Medical Supply Or Device Loan | $1,363.06 |
| Education | $278.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,930.80 | 2019-2025 | |
| Janssen Biotech, INC. | $1,047.18 | 2019-2025 | Erleada, Tecvayli, Akeega |
| Astrazeneca Pharmaceuticals Lp | $618.43 | 2019-2025 | Enhertu, Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $585.51 | 2019-2025 | Opdivo |
| Incyte Corporation | $503.75 | 2019-2025 | Jakafi, Monjuvi, Monjuvi |
| Helsinn Therapeutics (U.S.), INC. | $391.33 | 2019-2023 | Akynzeo |
| Glaxosmithkline, LLC. | $376.84 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $373.69 | 2019-2023 | Lumakras |
| Pfizer INC. | $331.96 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $321.08 | 2019-2025 | Onivyde, Somatuline Depot |
| Daiichi Sankyo INC. | $318.27 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $316.26 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Lilly USA, LLC | $304.67 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $281.35 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $258.26 | 2022-2025 | Lynozyfic, Libtayo |
Show all 83 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Fleener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.